Parathyroid Hormone (PTH)
Parathyroid hormone (PTH) and its analogue, teriparatide, are a new class of osteoporosis treatments called bone formation agents. Teriparatide injection (Forteo) is the first medication approved by Health Canada in this new class.
How does teriparatide injection work?
The mechanism by which bone is constantly renewed is called bone remodelling. Teriparatide injection works in a novel way on the bone remodelling process so that new bone is generated and added to the skeleton faster than old bone is broken down. It does this by activating the osteoblast (bone-building) cells.
How effective is it?
Teriparatide injection has been shown to increase bone density and reduce the risk of both vertebral fractures and other fractures associated with osteoporosis.
Who can take it?
It is used for the treatment of postmenopausal women with severe osteoporosis who are at high risk of fracture or who have failed or are intolerant to previous osteoporosis therapy. It is also used to increase bone mass in men with primary or hypogonadal (low testosterone) severe osteoporosis who have failed or are intolerant to previous osteoporosis therapy. It is also indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in men and women who are at increased risk of fracture.
How is it taken?
It is taken as a sub-cutaneous injection into the thigh or abdominal wall, 20 mcg (micrograms) once a day. This medication should not be taken for longer than 24 months.
Are there side effects?
Possible side effects include dizziness, nausea and leg cramps.
Bisphosphonates are a family of drugs used to treat osteoporosis. There are four bisphosphonates currently approved for use in Canada: alendronate (Fosamax ®), etidronate (Didrocal ®), risedronate...Read More
Hormone Therapy (HT) or estrogen/progesterone, is commonly used to relieve the symptoms of menopause. However, because estrogen plays such an important role in maintaining bone, HT is another option...Read More
Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction and thereby inhibits osteoclast formation. Denosumab (Prolia™) is the first...Read More